BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » Islet inflammation in plain sight

Islet inflammation in plain sight

The exact cause of either type 1 or type 2 diabetes still remains unknown. Inflammation of the insulin-producing islets of Langerhans seems to be one of the common denominators during the early stage of both diseases. InSight Technology is a promising analytical tool for studying the inflammation processes. The review is published in Diabetes, Obesity and Metabolism in September 2013.

Chronic exposure to high levels of blood sugar is a primary cause for the many complications of the two types of diabetes. Even though it is still not fully understood, which factors contribute to development of both type 1 and type 2 diabetes, some common denominators have been identified.

One of the factors is the presence of slowly progressing inflammation in the pancreatic islets of Langerhans. It contributes to the loss of function and subsequently death of insulin-producing beta-cells inside the islets. Two of the previously reported reasons for inflammation are:

  1. Increased infiltration of immune cells, which leads to high concentrations of signalling substances cytokines and chemokines.  Inside the beta-cells, these substances induce STAT1 and NF-kB signalling pathways involved in among others cell survival and cell death, apoptosis;
  2. High levels of blood serum factor apolipoprotein CIII (apoCIII), which contributes to chronically increased calcium ions concentrations inside the beta-cells. This in turn leads to beta-cell dysfunction and subsequent death.

InSight Technology provides an excellent tool to study the inflammatory processes non-invasively, longitudinally and with single-cell resolution.  The immune privileged status of the anterior chamber of the eye is compromised when pancreatic islets are implanted for examination. Thus, the immune cells have a possibility to infiltrate the islets in the eye and the inflammation processes can be studied over time.

The review article is published in the Diabetes, Obesity and Metabolism in September 2013.

Read more:  Islet inflammation in plain sight. Abdulreda MH, Berggren PO. Diabetes Obes Metab. 2013 Sep;15 Suppl 3:105-16

November 28, 2013 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved